Population pharmacokinetics of cabazitaxel in patients with advanced solid tumors
Open Access
- 9 January 2013
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 71 (3) , 681-692
Abstract
Purpose To develop a population pharmacokinetic (PK) model for cabazitaxel in patients with advanced solid tumors and examine the influence of demographic and baseline parameters. Methods One hundred and seventy patients who received cabazitaxel (10–30 mg/m2, 1-h IV infusion) every 7 or 21 days in five Phase I–III studies were analyzed by non-linear mixed-effect modeling (NONMEM VI). Model evaluation comprised non-parametric bootstrap and visual predictive checks. Results Cabazitaxel PK was best described by a linear three-compartment model with: first-order elimination; interindividual variability on clearance (CL), central volume of distribution (V1), and all intercompartmental rate constants except K21; interoccasion variability in CL and V1; proportional residual error of 27.8 %. Cabazitaxel CL was related to body surface area (BSA) and tumor type (breast cancer; finding confounded by study). Typical CL for a non-breast cancer patient with a BSA of 1.84 m2 was 48.5 L/h, with V1 26.0 L, steady-state volume of distribution 4,870 L and alpha, beta, and gamma half-lives of 4.4 min, 1.6, and 95 h, respectively. Sex, height, weight, age, Caucasian race, renal/hepatic function, and cytochrome P450 inducer use did not significantly further explain the PK of cabazitaxel. Bootstrap and posterior predictive checks confirmed the adequacy of the model. Conclusions Cabazitaxel PK appears unaffected by most baseline patient factors, and the influence of BSA on CL is addressed in practice by BSA-dependent doses. This analysis suggests consistent cabazitaxel PK and exposure across most solid tumor types, although the potential influence of breast cancer on CL requires further confirmation.Keywords
This publication has 16 references indexed in Scilit:
- A phase I open-label study investigating the disposition of [14C]-cabazitaxel in patients with advanced solid tumorsAnti-Cancer Drugs, 2015
- Cabazitaxel in patients with advanced solid tumours: Results of a Phase I and pharmacokinetic studyEuropean Journal of Cancer, 2013
- A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: A phase I/II studyEuropean Journal of Cancer, 2011
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trialThe Lancet, 2010
- Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid TumorsClinical Cancer Research, 2009
- A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patientsAnnals of Oncology, 2008
- A Linux cluster for population pharmacokinetic analyses.2004
- Clinical Pharmacokinetics of CapecitabineClinical Pharmacokinetics, 2001
- Statistical Graphics in Pharmacokinetics and Pharmacodynamics: A TutorialAnnals of Pharmacotherapy, 1998
- The Use of Population Pharmacokinetics in Drug DevelopmentClinical Pharmacokinetics, 1996